BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9806558)

  • 1. Contraceptive efficacy of low doses of mifepristone.
    Marions L; Danielsson KG; Swahn ML; Bygdeman M
    Fertil Steril; 1998 Nov; 70(5):813-6. PubMed ID: 9806558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation.
    Gemzell-Danielsson K; Swahn ML; Svalander P; Bygdeman M
    Hum Reprod; 1993 Jun; 8(6):870-3. PubMed ID: 8345076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a single post-ovulatory dose of RU486 on endometrial maturation in the implantation phase.
    Gemzell-Danielsson K; Svalander P; Swahn ML; Johannisson E; Bygdeman M
    Hum Reprod; 1994 Dec; 9(12):2398-404. PubMed ID: 7714164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of long-term low-dose mifepristone on reproductive function in women.
    Croxatto HB; Kovács L; Massai R; Resch BA; Fuentealba B; Salvatierra AM; Croxatto HD; Zalányi S; Viski S; Krenács L
    Hum Reprod; 1998 Apr; 13(4):793-8. PubMed ID: 9619526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
    Croxatto HB; Massai MR; Salvatierra AM; Fuentealba B; Croxatto HD; Lähteenmäki P
    Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
    Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception.
    Webb AM; Russell J; Elstein M
    BMJ; 1992 Oct; 305(6859):927-31. PubMed ID: 1458074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of two antiprogestins (mifepristone and onapristone) on endometrial factors of potential importance for implantation.
    Cameron ST; Critchley HO; Buckley CH; Kelly RW; Baird DT
    Fertil Steril; 1997 Jun; 67(6):1046-53. PubMed ID: 9176442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-implantation activity of antiestrogens and mifepristone.
    Dao B; Vanage G; Marshall A; Bardin CW; Koide SS
    Contraception; 1996 Oct; 54(4):253-8. PubMed ID: 8922879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
    Luukkainen T; Heikinheimo O; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contraceptive efficacy of daily administration of 0.5 mg mifepristone.
    Marions L; Viski S; Danielsson KG; Resch BA; Swahn ML; Bygdeman M; Kovâcs L
    Hum Reprod; 1999 Nov; 14(11):2788-90. PubMed ID: 10548623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
    Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
    Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of ovulation by low-dose mifepristone (RU 486).
    Ledger WL; Sweeting VM; Hillier H; Baird DT
    Hum Reprod; 1992 Aug; 7(7):945-50. PubMed ID: 1331167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486: a potential new contraceptive strategy.
    Batista MC; Cartledge TP; Zellmer AW; Merino MJ; Axiotis C; Loriaux DL; Nieman LK
    Am J Obstet Gynecol; 1992 Jul; 167(1):60-5. PubMed ID: 1442957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
    Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
    Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RU 486: an overview of mifepristone and its potential applications.
    Contracept Rep; 1993 May; 4(2):7-9. PubMed ID: 12286473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-a-month treatment with a combination of mifepristone and the prostaglandin analogue misoprostol.
    Swahn ML; Bygdeman M; Chen JK; Gemzell-Danielsson K; Song S; Yang QY; Yang PJ; Qian ML; Chang WF
    Hum Reprod; 1999 Feb; 14(2):485-8. PubMed ID: 10099999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mode of action of RU 486.
    Bygdeman M; Swahn ML; Gemzell-Danielsson K; Svalander P
    Ann Med; 1993 Feb; 25(1):61-4. PubMed ID: 8435191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-implantation activity of luteal phase mifepristone administration is not mimicked by prostaglandin synthesis inhibitor or prostaglandin analogue in the rhesus monkey.
    Nayak NR; Ghosh D; Lasley BL; Sengupta J
    Contraception; 1997 Feb; 55(2):103-14. PubMed ID: 9071520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mifepristone: a potential contraceptive.
    Heikinheimo O; Archer DF
    Clin Obstet Gynecol; 1996 Jun; 39(2):461-8. PubMed ID: 8734010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.